How Will the 21st Century Cures Act Impact Workers’ Comp?

by Devin Motley
Regulatory Counsel

On December 13, 2016, President Obama signed H.R.34, known as the 21st Century Cures Act, into law. Advertised as a victory for bi-partisan cooperation in Congress, the legislation aims to tackle critical health issues facing American society including combating the opioid epidemic, funding cancer research, addressing mental health care, and modifying what approval is required …

Proposed Legislation in Pennsylvania: Senate Bill 1349

by Devin Motley
Regulatory Counsel

Pennsylvania Senate Bill 1349 introduced 10/12/16 would make Pennsylvania the latest state to limit opioid prescriptions. There are three key points to the legislation: Seven-Day Limitation As a general rule, medical professionals “may not prescribe to an individual more than a seven-day supply of a controlled substance containing an opioid.” If a prescriber in their …

FDA Black Box Warnings for Combined Opioid and Benzodiazepine Use

by Michael Nguyen, PharmD, CPh, Director of Clinical Services
Andi Moore, PharmD

Michael Nguyen

After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced on August 31, 2016, that class-wide changes to drug labeling, including patient information, was being required for the opioid and benzodiazepine therapeutic classes because of serious risks associated with using medications from these two classes at the same time. …

DEA Rejects Proposal to Change Classification of Marijuana

by Brian Williams
PharmD, Research Fellow

Marijuana remains a Schedule I drug In a letter from Acting Administrator Chuck Rosenberg, the U.S. Drug Enforcement Administration (DEA) has rejected a proposal to change the federal classification of marijuana from a Schedule I to a Schedule II drug. By keeping it in Schedule I, the DEA is maintaining that marijuana has no currently …

New “N” Drug Classifications in Texas and Oklahoma: Essential Information for Claims Professionals

by Phil Walls, RPh
Chief Clinical Officer

The Texas Department of Insurance Division of Workers’ Compensation has announced that both Duragesic® (fentanyl) transdermal system patches and MS Contin® (morphine sulfate) extended-release tablets will be classified as “N” Drugs, effective February 1, 2016.  These drugs belong to a drug class known as long-acting opioids, which also includes current “N” Drugs like OxyContin® and …

California Formulary News

by myMatrixx

Legislation mandating a formulary, AB 1124, has been approved by the California legislature and has been sent to Governor Jerry Brown (D).   AB 1124 provides the framework for the Division of Workers’ Compensation to approve a drug formulary using evidence-based medicine. The formulary will be a part of the medical treatment utilization schedule (MTUS) and …

States Continue to Take a Stand Against the Prescription Opioid Epidemic

by Tammy Odierna
Regulatory Data Analyst

Earlier this month, Connecticut Governor Dannel Malloy hosted a bill signing ceremony to celebrate passage of PDMP legislation: CT HB 6856. Governor Malloy championed the bill as “common sense legislation” that “will help save lives and address a pressing public health need.” Governor Malloy said, “We have to treat addiction like a public health issue …

New Issue of myMatrixx Monitor

by myMatrixx

In the new issue of the myMatrixx Monitor newsletter our clinical team reviews Nucynta ER and its effectiveness for neuropathic pain, we provide a summary of the 2013 legislative session, and take a look at a home our employees built for Habitat for Humanity. Read the new issue here…

Texas Regulatory Update

by Jaelene Fayhee

The Texas Department of Insurance-Division of Workers’ Compensation held a Quarterly Insurance Carrier meeting on October 23, 2013. Presentations from the meeting will be posted on TDI-DWC’s System Monitoring and Oversight webpage. To help you sift through all this information, myMatrixx’s Jaelene Fayhee, Compliance and Govt. Affairs Director, has provided a summary of key points …

N-Drugs, Return to Work, OxyContin Saga and More

by myMatrixx

In the Fall Issue of myMatrixx’s newsletter, The Monitor, our clinical team reviews the Texas Closed Formulary and explains some of the confusion around N-drugs. We also take a look at the continuing Oxycontin saga, share best practices from industry leaders on Return to Work programs, and explain recent legislation adopted in California and Texas. …